Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE: 300255)
China
· Delayed Price · Currency is CNY 20.31
+0.49 (2.47%)
Dec 27, 2024, 3:04 PM CST
Hebei Changshan Biochemical Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -844.59 | -1,240 | 17.51 | 233.57 | 252.84 | 225.29 | Upgrade
|
| Depreciation & Amortization | 74.56 | 74.56 | 56.94 | 55.8 | 55.28 | 52.29 | Upgrade
|
| Other Amortization | 1.04 | 1.04 | 0.62 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.01 | -0.01 | 0.01 | - | - | 0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.79 | 1.79 | 2.12 | 0.11 | 0.02 | 0.21 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | - | - | 5 | Upgrade
|
| Provision & Write-off of Bad Debts | 15.38 | 15.38 | 6.51 | -0.13 | 2.67 | -1.1 | Upgrade
|
| Other Operating Activities | 608.53 | 730.45 | 98.1 | 62.96 | 57.34 | 49.22 | Upgrade
|
| Change in Accounts Receivable | 284.66 | 284.66 | -97.06 | 91.52 | -90.31 | -14.4 | Upgrade
|
| Change in Inventory | 161.28 | 161.28 | -156.01 | -398.02 | -479.01 | -324.78 | Upgrade
|
| Change in Accounts Payable | 13.82 | 13.82 | 72.17 | -48.54 | 23.62 | -44.98 | Upgrade
|
| Operating Cash Flow | 307.43 | 33.73 | 3.13 | 2.87 | -183.58 | -58.13 | Upgrade
|
| Operating Cash Flow Growth | 384.24% | 979.06% | 8.85% | - | - | - | Upgrade
|
| Capital Expenditures | -165.13 | -239.32 | -431.22 | -308.08 | -199.78 | -163.4 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.02 | 0.02 | 0 | - | - | - | Upgrade
|
| Investment in Securities | 0 | 0 | - | - | - | 254.2 | Upgrade
|
| Other Investing Activities | 0.48 | 0.45 | -0.1 | 0.78 | -3.07 | 0.59 | Upgrade
|
| Investing Cash Flow | -164.63 | -238.85 | -431.32 | -307.31 | -202.85 | 91.39 | Upgrade
|
| Long-Term Debt Issued | - | 1,346 | 2,816 | 1,581 | 1,579 | 817.8 | Upgrade
|
| Total Debt Issued | 1,863 | 1,346 | 2,816 | 1,581 | 1,579 | 817.8 | Upgrade
|
| Long-Term Debt Repaid | - | -1,529 | -2,030 | -1,182 | -1,099 | -954.5 | Upgrade
|
| Total Debt Repaid | -1,842 | -1,529 | -2,030 | -1,182 | -1,099 | -954.5 | Upgrade
|
| Net Debt Issued (Repaid) | 20.58 | -182.36 | 786.08 | 399.46 | 480.14 | -136.69 | Upgrade
|
| Common Dividends Paid | -107.24 | -107.73 | -124 | -61.89 | -68.46 | -71.6 | Upgrade
|
| Other Financing Activities | -20.79 | -4.85 | -8.63 | 5.39 | -120.01 | -3 | Upgrade
|
| Financing Cash Flow | -107.46 | -294.94 | 653.44 | 342.96 | 291.67 | -211.3 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.13 | 3.03 | 12.96 | -3.49 | -1.76 | 0.58 | Upgrade
|
| Net Cash Flow | 35.48 | -497.03 | 238.2 | 35.04 | -96.52 | -177.45 | Upgrade
|
| Free Cash Flow | 142.3 | -205.6 | -428.1 | -305.21 | -383.36 | -221.53 | Upgrade
|
| Free Cash Flow Margin | 13.49% | -14.58% | -18.32% | -10.28% | -16.22% | -10.69% | Upgrade
|
| Free Cash Flow Per Share | 0.18 | -0.22 | -0.49 | -0.33 | -0.41 | -0.24 | Upgrade
|
| Cash Income Tax Paid | 13.28 | 149.83 | 70.81 | 163.73 | 207.02 | 192.4 | Upgrade
|
| Levered Free Cash Flow | 305.74 | 55.82 | -500.03 | -469.98 | -472.58 | -301.21 | Upgrade
|
| Unlevered Free Cash Flow | 360.57 | 116.08 | -441.88 | -431.04 | -437.7 | -272.09 | Upgrade
|
| Change in Net Working Capital | -1,039 | -995.37 | 135.71 | 381.3 | 523.69 | 351.69 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.